Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lubomir Sokol

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Blood|September 24, 2011
Fox and Blimp in NK-cell lymphomaLubomir Sokol
Cancer Control : Journal of the Moffitt Cancer Center|October 14, 2014
Hope for orphan lymphoproliferative and histiocytic diseases on the horizon?Lubomir Sokol
Expert Opinion on Investigational Drugs|March 9, 2016
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphomaSusmitha Apuri, Lubomir Sokol
Expert Opinion on Investigational Drugs|August 18, 2018
The advances in therapy of blastic plasmacytoid dendritic cell neoplasmDaniel Kerr, Lubomir Sokol
Cancer Management and Research|July 5, 2022
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell NeoplasmYumeng Zhang, Lubomir Sokol
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2020
Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available RegimensHayder Saeed, Lubomir Sokol
Cancer Control : Journal of the Moffitt Cancer Center|June 20, 2012
B-cell non-hodgkin lymphoma: targeting in on the futureCeleste Bello, Lubomir Sokol
Cancers|May 13, 2026
Revisiting the Origins of Cutaneous T-Cell Lymphoma: A Progenitor-Based ModelYumeng Zhang, Lubomir Sokol
Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2007
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromesSandra Kurtin, Lubomir Sokol
Immunotargets and Therapy|July 15, 2021
Targeting CD22 for the Treatment of B-Cell MalignanciesNikesh N Shah, Lubomir Sokol
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Blood|September 24, 2011
Fox and Blimp in NK-cell lymphomaLubomir Sokol
Cancer Control : Journal of the Moffitt Cancer Center|October 14, 2014
Hope for orphan lymphoproliferative and histiocytic diseases on the horizon?Lubomir Sokol
Expert Opinion on Investigational Drugs|March 9, 2016
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphomaSusmitha Apuri, Lubomir Sokol
Expert Opinion on Investigational Drugs|August 18, 2018
The advances in therapy of blastic plasmacytoid dendritic cell neoplasmDaniel Kerr, Lubomir Sokol
Cancer Management and Research|July 5, 2022
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell NeoplasmYumeng Zhang, Lubomir Sokol
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2020
Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available RegimensHayder Saeed, Lubomir Sokol
Cancer Control : Journal of the Moffitt Cancer Center|June 20, 2012
B-cell non-hodgkin lymphoma: targeting in on the futureCeleste Bello, Lubomir Sokol
Cancers|May 13, 2026
Revisiting the Origins of Cutaneous T-Cell Lymphoma: A Progenitor-Based ModelYumeng Zhang, Lubomir Sokol
Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2007
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromesSandra Kurtin, Lubomir Sokol
Immunotargets and Therapy|July 15, 2021
Targeting CD22 for the Treatment of B-Cell MalignanciesNikesh N Shah, Lubomir Sokol
Pageof 20